|
Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon. |
|
|
Consulting or Advisory Role - Amgen; Bayer; Novartis; Roche; Sanofi; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Lilly; Merck; Roche; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Merck; Roche; SERVIER |
Research Funding - Amgen (Inst); Bayer (Inst); Merck (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Novartis |
Consulting or Advisory Role - Novartis |
Speakers' Bureau - AstraZeneca; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Dompè; Ignyta; Novartis; Pfizer; SERVIER; Tiziana Life Sciences |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; SERVIER |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar; Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck (I); Pfizer; Roche; Sanofi; SERVIER |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Roche (Inst); Takeda (Inst) |